JonVillenaMD
@JonVillenaMD
Followers
51
Following
304
Media
6
Statuses
37
Joined May 2025
Was a great session on the tumor microenvironment @AATSHQ this morning! Important to dedicate time to translational topics that more and more are becoming part of thoracic surgery and quality lung cancer care. Thanks to the organizers for making this a priority! #ITSOS2025
0
4
24
Congratulations to AATS Vice President Leonard Girardi of @WCM_CTSurgery for being recognized as the top #cardiothoracic surgeon in the U.S. by @Newsweek. Many AATS Members are also highlighted. See the full list below.
Navigating a serious health issue can be daunting, especially with so many specialists and treatment options to consider. To help patients find top-tier care, Newsweek and Statista are proud to present America’s Leading Doctors 2025. More: https://t.co/bEQB1m4PO7
0
4
11
The Single Port Robot has arrived @WCM_CTSurgery First 25 cases: 21 lung resections, 3 mediastinal masses, 1 diaphragm plication. Less pain. The future of thoracic surgery? @GavittWoodard @ElliotServaisMD @hari_keshava @DoctorJSpicer @BrendonStilesMD
1
1
9
Surgeons, QUICK Q: How long would it take you to perform JUST an MIS hilar + mediastinal lymph node dissection (1-2N1 + 3N2) alone "skin to skin " (no lung resection)? @ElliotServaisMD @BrendonStilesMD @hari_keshava @GavittWoodard @DoctorJSpicer
0
2
2
Looking forward to an outstanding virtual summit on a hot topic - designing the newest clinical trials in earlier stage cancers that can be removed by surgery. Truly world leading panel to discuss key areas in this rapidly changing field. Join us for free online! @sitcancer #lcsm
Tomorrow is the #SITC Summit on the Future of Neoadjuvant Clinical Trial Design, which will discuss the recent advances in clinical trials for resectable tumors. The Neoadjuvant Clinical Trial Design Working Group is chaired by Patrick Forde, MD. Register: https://t.co/m9VDVO2Q23
1
9
39
Thrilled to celebrate @DrKarenKnudsen — our CEO — as a @CNBC 2025 Changemaker! Her mission: get innovation to those who need it most. In under 10 years, PICI has backed 1,000+ investigators, 17 startups, and $4B+ in follow-on capital — all by de-risking science from day one.
cnbc.com
Karen Knudsen is leading Sean Parker's cancer immunotherapy incubator where philanthropy and venture capital meet.
1
1
11
0
0
1
🧬 Single-cell RNA/TCR-seq clonal mapping from treated & untreated patients • LNs are a reservoir of tumor-specific CD8⁺ T cells • ChemoIO selectively expands LN-derived TCR diversity • LN clones reprogram into cytotoxic memory cells that circulate in blood
1
0
2
Where does the T cell response come from after neoadjuvant chemoIO? Our new study in resectable NSCLC shows that benign tumor-draining lymph nodes —not just tumors—initiate and program the anti–PD-1 response. https://t.co/E8hIyyyin4
1
4
13